Regional brain metabolism as the predictor of performance on the Trail Making Test in schizophrenia. A 18FDG PET covariation study

Neuroendocrinology Letters

Volumn 27, Issue 5, 2006, Pages 587-594

  Horacek, Jiri ^a,b   Dockery, Colleen ^a   Kopecek, Milan ^a,b   Spaniel, Filip ^a,b   Novak, Tomas ^b   Tislerova, Barbora ^a,b   Klirova, Monika ^a,b   Palenicek, Tomas ^b   Höschl, Cyril ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

18FDG; Cognitive dysfunction; Positron emission tomography (PET); Schizophrenia; Trail Making Test

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUORODEOXYGLUCOSE F 18; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; OXYPROTHEPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; BRAIN METABOLISM; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FRONTAL LOBE; HUMAN; LIMBIC CORTEX; MALE; MENTAL PERFORMANCE; PARIETAL LOBE; PATHOGENESIS; PONS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PSYCHOLOGIC TEST; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; TEMPORAL CORTEX;

EID: 33845992563     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Callaway E, Naghdi S. An information processing model for schizophrenia. Arch Gen Psychiatry 1982; 39(3):339-347.
2. Lieh-Mak F, Lee PW. Cognitive deficit measures in schizophrenia: factor structure and clinical correlates. Am J Psychiatry 1997; 154(6 Suppl):39-46.
3. Mohamed S, Paulsen JS, O'Leary D, Arndt S, Andreasen N. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch Gen Psychiatry 1999; 56(8):749-754.
4. Tollefson GD. Cognitive function in schizophrenic patients. J Clin Psychiatry 1996; 57 Suppl 11:31-39.
5. Buchanan RW, Carpenter WT, Jr. The neuroanatomies of schizophrenia. Schizophr Bull 1997; 23(3):367-372.
6. Frith CD. Functional brain imaging and the neuropathology of schizophrenia. Schizophr Bull 1997; 23(3):525-527.
7. Stevens JR. Anatomy of schizophrenia revisited. Schizophr Bull 1997; 23(3):373-383.
8. Weinberger DR, Berman KF, Suddath R, Torrey EF. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 1992; 149(7):890-897.
9. Heckers S, Rauch SL, Goff D et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci 1998; 1(4):318-323.
10. Horáček J, Kopeček M, Španiel F et al. Resting regional brain metabolism in patients with schizophrenia. 18FDG PET study. Psychiatrie 2004;8(Suppl.3):43-50.
11. Catafau AM, Parellada E, Lomena FJ et al. Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-naive patients with acute disease. J Nucl Med 1994; 35(6):935-941.
12. Paulman RG, Devous MD, Sr., Gregory RR et al. Hypofrontality and cognitive impairment in schizophrenia: dynamic single-photon tomography and neuropsychological assessment of schizophrenic brain function. Biol Psychiatry 1990; 27(4):377-399.
13. Franck N, O'Leary DS, Flaum M, Hichwa RD, Andreasen NC. Cerebral blood flow changes associated with Schneiderian first-rank symptoms in schizophrenia. J Neuropsychiatry Clin Neurosci 2002; 14(3):277-282,
14. Schroder J, Buchsbaum MS, Siegel BV et al. Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia. Schizophr Res 1996; 19(1):41-53.
15. Schroder J, Buchsbaum MS, Siegel BV, Geider FJ, Niethammer R. Structural and functional correlates of subsyndromes in chronic schizophrenia. Psychopathology 1995; 28(1):38-45.
16. Levitt JJ, McCarley RW, Nestor PG et al. Quantitative volumetric MRI study of the cerebellum and vermis in schizophrenia: clinical and cognitive correlates. Am J Psychiatry 1999; 156(7):1105-1107.
17. Buchsbaum MS. Frontal lobes, basal ganglia, temporal lobes - three sites for schizophrenia? Schizophr Bull 1990; 16(3):377-378.
18. Buchsbaum MS, Nuechterlein KH, Haier RJ et al. Glucose metabolic rate in normals and schizophrenics during the Continuous Performance Test assessed by positron emission tomography. Br J Psychiatry 1990; 156:216-227.
19. Crespo-Facorro B, Wiser AK, Andreasen NC et al. Neural basis of novel and well-learned recognition memory in schizophrenia: a positron emission tomography study. Hum Brain Mapp 2001; 12(4):219-231.
20. Zorrilla LT, Jeste DV, Brown GG. Functional MRI and novel picture-learning among older patients with chronic schizophrenia: abnormal correlations between recognition memory and medial temporal brain response. Am J Geriatr Psychiatry 2002; 10(1):52-61.
21. Honey GD, Bullmore ET, Sharma T. De-coupling of cognitive performance and cerebral functional response during working memory in schizophrenia. Schizophr Res 2002; 53(1-2):45-56.
22. Kindermann SS, Karimi A, Symonds L, Brown GG, Jeste DV. Review of functional magnetic resonance imaging in schizophrenia. Schizophr Res 1997; 27(2-3):143-156.
23. Egan MF, Goldberg TE, Kolachana BS et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001; 98(12):6917-6922.
24. Weinberger DR, Gallhofer B. Cognitive function in schizophrenia. Int Clin Psychopharmacol 1997; 12 Suppl 4:S29-S36.
25. Andreasen NC. Schizophrenia: the fundamental questions. Brain Res Brain Res Rev 2000; 31(2-3):106-112.
26. Dolan RJ, Fletcher PC, McKenna P, Friston KJ, Frith CD. Abnormal neural integration related to cognition in schizophrenia. Acta Psychiatr Scand Suppl 1999; 395:58-67.
27. Goldman-Rakic PS, Selemon LD. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 1997; 23(3):437-458.
28. Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958; 8:271-276.
29. Reitan RM, Wolfson D. Category Test and Trail Making Test As Measures of Frontal-Lobe Functions. Clinical Neuropsychologist 1995; 9(1):50-56.
30. Kim MS, Kang SS, Youn T, Kang DH, Kim JJ, Kwon JS. Neuropsychological correlates of P300 abnormalities in patients with schizophrenia and obsessive-compulsive disorder. Psychiatry Res 2003; 123(2)109-123.
31. Keefe RS, Silverman JM, Roitman SE et al. Performance of non-psychotic relatives of schizophrenic patients on cognitive tests. Psychiatry Res 1994; 53(1):1-12.
32. Oades RD, Rao ML, Bender S, Sartory G, Muller BW. Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy. Behav Pharmacol 2000; 11(3-4):317-330.
33. Mahurin RK, Velligan DI, Miller AL. Executive-frontal lobe cognitive dysfunction in schizophrenia: a symptom subtype analysis. Psychiatry Res 1998; 79(2):139-149.
34. Gochman PA, Greenstein D, Sporn A et al. Childhood onset schizophrenia: familial neurocognitive measures. Schizophr Res 2004; 71(1):43-47.
35. Moll J, Oliveira-Souza R, Moll FT, Bramati IE, Andreiuolo PA. The cerebral correlates of set-shifting: an fMRI study of the trail making test. Arq Neuropsiquiatr 2002; 60(4):900-905.
36. Shulman RG. Functional imaging studies: linking mind and basic neuroscience. Am J Psychiatry 2001; 158(1):11-20.
37. Rocher AB, Chapon F, Blaizot X, Baron JC, Chavoix C. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage 2003; 20(3):1894-1898.
38. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2):261-276.
39. Braff DL, Heaton R, Kuck J et al. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Arch Gen Psychiatry 1991; 48(10):891-898.
40. Zalla T, Joyce C, Szoke A et al. Executive dysfunctions as potential markers of familial vulnerability to bipolar disorder and schizophrenia. Psychiatry Res 2004; 121(3):207-217.
41. Wolwer W, Gaebel W. Impaired visuomotor integration in acute schizophrenia. World J Biol Psychiatry 2003; 4(3):124-128.
42. Wolwer W, Falkai P, Streit M, Gaebel W. Trait characteristic of impaired visuomotor integration during Trail-Making Test B performance in schizophrenia. Neuropsychobiology 2003; 48(2):59-67.
43. Brazo P, Marie RM, Halbecq I et al. Cognitive patterns in subtypes of schizophrenia. Eur Psychiatry 2002; 17(3):155-162.
44. Moritz S, Andresen B, Jacobsen D et al. Neuropsychological correlates of schizophrenic syndromes in patients treated with atypical neuroleptics. Eur Psychiatry 2001; 16(6):354-361.
45. Sweeney JA, Haas GL, Keilp JG, Long M. Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: one-year followup study. Psychiatry Res 1991; 38(1):63-76.
46. Allen DN, Gilbertson MW, van Kammen DP, Kelley ME, Gurklis JA, Jr., Barry EJ. Chronic haloperidol treatment does not affect structure of attention in schizophrenia. Schizophr Res 1997; 25(1):53-61.
47. Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM. Neuroleptic drug effects on cognitive function in schizophrenia. Schizophr Res 1990; 3(3):211-219.
48. Gilbertson MW, van Kammen DP. Recent and remote memory dissociation: medication effects and hippocampal function in schizophrenia. Biol Psychiatry 1997; 42(7):585-595.
49. Sweeney JA, Keilp JG, Haas GL, Hill J, Weiden PJ. Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Res 1991; 37(3):297-308.
50. Andreasen NC, O'Leary DS, Cizadlo T et al. Remembering the past: two facets of episodic memory explored with positron emission tomography. Am J Psychiatry 1995; 152(11):1576-1585.
51. Magistretti PJ, Pellerin L, Rothman DL, Shulman RG. Energy on demand. Science 1999; 283(5401):496-497.
52. Wolwer W, Gaebel W. Impaired Trail-Making Test-B performance in patients with acute schizophrenia is related to inefficient sequencing of planning and acting. J Psychiatr Res 2002; 36(6):407-416.
53. Friston KJ, Holmes A, Poline JB, Price CJ, Frith CD. Detecting activations in PET and fMRI: levels of inference and power. Neuroimage 1996; 4(3 Pt 1):223-235.
54. Ebert D, Feistel H, Kaschka W. Left temporal hypoperfusion in catatonic syndromes: a SPECT study. Psychiatry Res 1992; 45(4):239-241.
55. Wolkin A, Jaeger J, Brodie JD et al. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatry 1985; 142(5):564-571.
56. Wolkin A, Angrist B, Wolf A et al. Low frontal glucose utilization in chronic schizophrenia: a replication study. Am J Psychiatry 1988; 145(2):251-253.
57. Molina V, Sanz J, Reig S et al. Hypofrontality in men with first-episode psychosis. Br J Psychiatry 2005; 186:203-208.
58. Davidson LL, Heinrichs RW. Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res 2003; 122(2):69-87.
59. Buchsbaum MS, Hazlett E. Theoretical approaches to regional cerebral metabolic rate in schizophrenia. International Review of Psychiatry 9[4]:339-354. 1997.
60. Španiel F, Tintěra J, Hájek T, Horacek J, Dezortova M, Hajek M. Language lateralization in monozygotic twins discordant for schizophrenia. Evidence from functional MRI. Lateralizace řeči u monozygotních dvojčat diskordantních pro schizofrenii. Studie sfunkční magnetickou rezonancí. Psychiatrie 2003; 7(4):301-303.
61. Mitchell RL, Elliott R, Woodruff PW. fMRI and cognitive dysfunction in schizophrenia. Trends Cogn Sci 2001; 5(2):71-81.
62. Kircher TT, Liddle PF, Brammer MJ, Williams SC, Murray RM, McGuire PK. Neural correlates of formal thought disorder in schizophrenia: preliminary findings from a functional magnetic resonance imaging study. Arch Gen Psychiatry 2001; 58(8):769-774.
63. Rubia K, Russell T, Bullmore ET et al. An fMRI study of reduced left prefrontal activation in schizophrenia during normal inhibitory function. Schizophr Res 2001; 52(1-2):47-55.
64. Spence SA, Hirsch SR, Brooks DJ, Grasby PM. Prefrontal cortex activity in people with schizophrenia and control subjects. Evidence from positron emission tomography for remission of 'hypofrontality' with recovery from acute schizophrenia. Br J Psychiatry 1998; 172:316-323.
65. Wible CG, Shenton ME, Hokama H et al. Prefrontal cortex and schizophrenia. A quantitative magnetic resonance imaging study. Arch Gen Psychiatry 1995; 52(4):279-288.
66. Wiesel FA, Wik G, Sjogren I, Blomqvist G, Greitz T, Stone-Elander S. Regional brain glucose metabolism in drug free schizophrenic patients and clinical correlates. Acta Psychiatr Scand 1987; 76(6):628-641.
67. Fletcher P, McKenna PJ, Friston KJ, Frith CD, Dolan RJ. Abnormal cingulate modulation of fronto-temporal connectivity in schizophrenia. Neuroimage 1999; 9(3):337-342.
68. Fletcher PC, Frith CD, Grasby PM, Friston KJ, Dolan RJ. Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia. J Neurosci 1996; 16(21):7055-7062.
69. Lawrie SM, Buechel C, Whalley HC, Frith CD, Friston KJ, Johnstone EC. Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations. Biol Psychiatry 2002; 51(12):1008-1011.
70. Meyer-Lindenberg A, Miletich RS, Kohn PD et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002; 5(3):267-271.
71. Yurgelun-Todd DA, Waternaux CM, Cohen BM, Gruber SA, English CD, Renshaw PF. Functional magnetic resonance imaging of schizophrenic patients and comparison subjects during word production. Am J Psychiatry 1996; 153(2):200-205.
72. Weinberger DR. The biological basis of schizophrenia: new directions. J Clin Psychiatry 1997; 58 Suppl 10:22-27.
73. Weinberger DR, Egan MF, Bertolino A et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001; 50(11):825-844.
74. Friston KJ, Liddle PF, Frith CD, Hirsch SR, Frackowiak RS. The left medial temporal region and schizophrenia. A PET study. Brain 1992; 115(Pt 2):367-382.
75. Weinberger DR. From neuropathology to neurodevelopment. Lancet 1995; 346(8974):552-557.